Degarelix (Firmagon)

General information

Class/mechanism: Gonadotropin-releasing hormone (GnRH) receptor antagonist. Reversibly binds to pituitary GnRH receptors, reducing the release of luteinizing hormone (LH) and follicle stimulation hormone (FSH), resulting in rapid androgen deprivation/decreased testosterone levels. There is no initial testosterone surge/flare with degarelix, in contrast to GnRH agonists.
Route: SC
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.

Diseases for which it is used

• Prostate cancer

Patient drug information

• Degarelix (Firmagon) package insert
• Degarelix (Firmagon) patient drug information (Chemocare)
• Degarelix (Firmagon) patient drug information (UpToDate)

History of changes in FDA indication

• 12/24/2008: FDA approved for treatment of patients with advanced prostate cancer. (Based on CS21)

Also known as

• Code name: ASP3550, FE200486
• Generic name: degarelix acetate
• Brand name: Firmagon